Patient Programs
Overview
KFRM supports three interconnected research and programme areas aimed at advancing scientific understanding in cancer immunology and contributing to the development of innovative immunotherapy approaches. These activities are carried out in collaboration with qualified medical institutions and are embedded in a broader clinical and research context.
Personalised Cancer Vaccine Research Program
Research is conducted into personalised vaccination approaches that are designed to induce tumour-specific immune responses targeting the individual molecular characteristics of tumours - including colorectal cancer (CRC), pancreatic cancer (PDAC), head and neck cancer (HNSCC), prostate cancer, ovarian cancer, breast cancer and renal cancer.
These approaches are developed and investigated within a clinical research framework by qualified medical institutions. Krebsforschung Rhein-Main e.V. supports the scientific and research-related aspects of these activities.
Over 25+ years of laboratory research at Krankenhaus Nordwest, these approaches have been systematically developed and investigated, contributing to the scientific understanding of tumour immunology.
Exercise and Support Programmes (Clinical Context)
Exercise and supportive programmes are implemented within a broader clinical and research context to contribute to the overall wellbeing of patients undergoing medical care.
These programmes are delivered by qualified specialists and are aligned with current clinical knowledge. Krebsforschung Rhein-Main e.V. supports these activities as part of its broader commitment to research and patient-centred programme development.
The aim is to complement clinical care through structured programme support within a research-informed environment.
Adoptive T Cell Therapy Trial (Planned Investigator Initiated Trial)
Coming SoonBuilding on long-standing research in tumour immunology, a Phase I investigator-initiated clinical study is being prepared to evaluate a novel adoptive T-cell therapy approach.
The study will investigate the use of T lymphocytes (T cells) that have been activated through prior vaccination approaches and expanded under GMP controlled laboratory conditions. The expanded T cells are the patient's own immune cells and are not genetically modified.
The clinical study represents the translation of extensive laboratory research into a controlled clinical research setting. Krebsforschung Rhein-Main e.V. supports the preparation and scientific development of this clinical study.
Get In Touch
We'd love to hear from you. Please fill out the form below and we'll get back to you as soon as possible.
This form is for general enquiries only. It is not intended for submission of medical or health-related information.